Technetium (99mTc)

BURNABY, British Columbia--(BUSINESS WIRE)-- ARTMS Products Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes. ARTMS will support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes for Telix’s portfolio of products, such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients. In addition, ARTMS’ portfolio of advanced cyclotron technologies has immediate application and differentiation for Telix in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At). The history of ARTMS is rooted in a Canadian government funded project focused on solid target production of 99mTc. After that project was successfully completed, the innovation continued and resulted in a full suite of PET products. In 2017, ARTMS Inc. was formed with support and seed funding from Quark Venture, through their Global Health Sciences Fund (GHS) and founding institutions TRIUMF, BC Cancer, Lawson Health Research Institute and the Center for Probe Development. In May of 2020, ARTMS completed a $20M USD Series A fundraising that included GHS and welcomed Deerfield Management to the ARTMS family. In the subsequent years ARTMS has played a critical role in alternative production of medical isotopes with a focus on accelerating the production capabilities of the world’s most commonly installed cyclotrons. The collaboration between ARTMS’ unparalleled team, its investors and founding members has resulted in a truly differentiated organization. Solomon Partners Securities LLC acted as financial advisor and Norton Rose Fulbright Canada LLP acted as legal advisor to ARTMS during the negotiations and due diligence process related to the acquisition by Telix. About ARTMS, Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry. For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter/X @ARTMS_Inc/X and LinkedIn and visit About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Radiopharmaceuticals are poised for a boom in the next decade! Analysts predict a surge in the market, driven by a perfect storm of factors. Public and private healthcare companies are pouring more money into this field, and cancer rates are rising globally. This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead. NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that. Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade. With industry giants, both public as well as private, pouring billions of dollars into the development of novel radio nucleotide-including treatments, the global valuation is very likely to reach US$ 11,635 million by 2034. The industry-academia collaboration, coupled with robust government policies, hefty healthcare expenditures, increasing awareness, and rising consumer spending on well-being is responsible for the market to grow at an anticipated CAGR of 3.40% through CAGR, especially in developing and developed economies like India, China, the United States, Spain, and the United Kingdom. "The market, which is still in its nascent stages, has great opportunities in the coming future. Companies in the market must collaborate with the government to make the offerings more affordable, feasible, and available," says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) . Key Takeaways from the Market Study The oncology segment dominates the global radiopharmaceutical market with a share of 51.40% in 2024. Based on radioisotope, the technetium-99 leads the radiopharmaceutical market with a share of 47.20% in 2024. The radiopharmaceutical market in India is anticipated to grow at a CAGR of 5.40% through 2034. The radiopharmaceutical market in Malaysia is estimated to rise at a 3.90% CAGR through 2034. The radiopharmaceutical market in Indonesia has the potential to increase at a 3.70% CAGR through 2034. The Thai radiopharmaceutical market is predicted to rise at a 3.20% CAGR through 2034. The radiopharmaceutical market in Spain is very likely to grow at a CAGR of 2.90% through 2034. Competitive Landscape The market for radiopharmaceuticals is still in its early stages with a few companies dominating the international marketplace. The requirement for radiopharmaceuticals is expected to increase significantly due to medical advancements and their wider usage in the medical world, which could provide excellent opportunities for new players to enter the market. Prominent companies in the market include Bayer AG, Bracco Imaging S.p.A., Cardinal Health, Inc., Eli Lilly and Company (Eli Lilly), Curium Pharma, Lantheus Holdings, Inc., Novartis AG, Nordion (Canada) Inc., etc. These companies provide radiopharmaceuticals to healthcare facilities such as hospitals, ambulatory surgical centers, clinics, specialty hospitals, etc. Key components in this market include innovation and keeping up with the latest medical technology. These companies are investing millions of dollars in the development of novel radiopharmaceuticals with improved efficiency. Recent Developments Bayer and PanTera partnered to obtain actinium-225 for radiopharmaceuticals, starting clinical trials in 2024. Ariceum Therapeutics opened a radiopharmaceutical lab in Berlin for R&D on upcoming pipeline candidates in March 2024. Ratio Therapeutics, in March 2024, extended its manufacturing deal with PharmaLogic to expedite production and launch of its FAP-targeted candidate. Purchase now and gain full access to the Radiopharmaceutical Industry report, featuring comprehensive Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives. About the Author: Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher. Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. Explore FMI's Extensive Coverage in the Healthcare Domain: Cancer Diagnostics Market by Tumor Biomarkers Tests, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, and Other Test Types, Forecast, 2023-2033. – Review and Request to Access the Sample Report. Cancer Vaccines Market by Technology, Treatment Method, Application & Region | Forecast 2023 to 2033. - Review and Request to Access the Sample Report. Cancer Biological Therapy market by Product Type, Vehicle Type, Sales Channel & Region | Forecast 2022 to 2032. - Review and Request to Access the Sample Report. Cancer Supportive Care Products Market By Drug Class, Indication, Distribution Channel & Region - Forecast to 2020-2030. - Review and Request to Access the Sample Report. Cancer Tissue Diagnostics Market by Immunohistochemical (IHC) Test and In Situ Hybridization (ISH) Test, Forecast, 2023-2033. - Review and Request to Access the Sample Report. Cancer-Focused Genetic Testing Services Market By Test Type, Cancer Type, Service Provider & Region | Forecast 2022 to 2032. - Review and Request to Access the Sample Report. About Future Market Insights (FMI) Future Market Insights (FMI) is a leading market intelligence and consulting service provider, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, the U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us Nandini Singh Sawlani Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-845-579-5705 For Sales Enquiries: [email protected] Website: LinkedIn | Twitter | Blogs | YouTube Logo: SOURCE Future Market Insights